Navigation Links
Chimerix Initiates Phase 1 Study of CMX157
Date:5/13/2010

CMX157 is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology to chemically modify tenofovir, the molecule underlying the prodrug Viread®, an antiviral agent approved for the treatment of HIV and chronic hepatitis B. Chimerix's PIM Conjugate Technology improves the absorption and distribution profile of drugs, achieving higher intracellular levels of the active antiviral agent. In vivo toxicology studies show that high plasma levels of CMX157 can be achieved with minimal toxicities.

CMX157 represents Chimerix's second antiviral compound to enter the clinic. Chimerix's lead compound, CMX001, a broad-spectrum antiviral agent with demonstrated in vitro activity against double-stranded DNA viruses, is in a multi-center Phase 2 clinical trial in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV) and is also in clinical development for the treatment of BK virus in renal transplant and stem cell transplant recipients.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on th
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
2. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
6. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
7. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
8. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
9. EnVivo Initiates Phase IIb Alzheimers Disease Trial For EVP-6124
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  An entire month ... of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – a ... legs, causing extreme muscle atrophy, weakness, and foot and ... US and millions worldwide. CMT is a progressive disease, ... their legs, requiring mobility devices such as leg braces, ...
(Date:9/19/2014)... Sept. 19, 2014 Pfenex Inc. (NYSE MKT: ... of high-value and difficult to manufacture proteins including biosimilar ... the 21 st Annual NewsMakers in the Biotech ... Bertrand Liang , chief executive officer of Pfenex, ... and business strategy on Friday, September 26, 2014 at ...
(Date:9/19/2014)... September 19, 2014 Cereal grain ... industries will gather October 5–8, 2014, for the ... Island Convention Center in Providence, Rhode Island. The ... work of food scientists, chemists, microbiologists, nutritionists, and ... food production management. To date, 1,000 attendees have ...
(Date:9/19/2014)... 2014 The new , Healthcare and ... available today on PharmaBoardroom.com for free download ... rocked the Spanish economy in 2009, and the austerity measures ... remained pragmatic in times of trouble. "Despite the ... biggest European market, and the general conditions to invest are ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Pfenex to Present at Upcoming Industry Conference on September 26 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... , , SAN DIEGO , ... BMR ) today announced the signing of an amendment to its ... 301 Binney Street laboratory research facility in Cambridge, Massachusetts . ... laboratory and office space contiguous to its existing premises located in ...
... , , ... Reportlinker.com announces that a new market research ... The Future of Nutrigenomics: New opportunities in ... http://www.reportlinker.com/p0177850/The-Future-of-Nutrigenomics-New-opportunities-in-personalized-nutrition-and-food-pharma-collaboration.html , Nutrigenomics explores how nutrients ...
... , CRANBURY, N.J. , Feb. 16 ... for its second quarter ended December 31, 2009 .  Palatin reported net ... diluted share, for the quarter ended December 31, 2009 , compared to ... basic and diluted share, for the same period in 2008.  Total revenues in ...
Cached Biology Technology:BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 3BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 2Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 3Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 4Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 5Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 7
(Date:9/17/2014)... atmospheric scientists were instrumental in the creation of the ... to classify the fire threat potential of the powerful, ... spark into an inferno. The index was introduced Sept. ... UCLA and San Diego Gas and Electric. , The ... "extreme" that will be used to help fire agencies ...
(Date:9/17/2014)... engineering professor and his doctoral student have designed a ... water collected from fog and dew., The device could ... deserts around the globe., Cheng Luo, professor in the ... candidate in the same College of Engineering department, published ... of ACS, (American Chemical Society) Applied Materials ...
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
Breaking Biology News(10 mins):UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... cells in the eye receptive to light is missing in ... animals like birds, fish and amphibians have two versions of ... The findings ?published in the Public Library of Science journal ... may be impoverished compared to other vertebrates and fits with ...
... Waiting a day or more to get lab results back ... a past. Using nanotechnology, a team of University of Georgia ... as diverse as influenza, HIV and RSV in 60 seconds ... ?which is detailed in the November issue of the journal ...
... 12, 2006 -- A new study in Journal of the ... over smaller shrimp of the same gender when competing for ... though adult males of the species are typically much smaller ... size and gender are important factors in acquiring food," says ...
Cached Biology News:Does missing gene point to nocturnal existence for early mammals? 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 3
... NightOWL is a dedicated imaging system ... size. Equipped with a very sensitive camera ... or plants in tumor research, infectious disease ... Western blots. NightOWL is the only imager ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: